# Drug-target affinity prediction method based on consistent expression of heterogeneous data

arXiv: https://arxiv.org/abs/2211.06792 · HTML: https://mlsanity.com/paper/2211.06792/

## Key facts

- No citing papers in the map yet (data through 14 Oct 2026).
- Builds on 4 of its 35 references that are in the map.
- First posted on arXiv 13 Nov 2022.

## Builds on (most cited first, 4 of 4)

- [Adam: A Method for Stochastic Optimization](https://mlsanity.com/paper/1412.6980/) (2014)
- [Batch Normalization: Accelerating Deep Network Training by Reducing Internal Covariate Shift](https://mlsanity.com/paper/1502.03167/) (2015)
- [How Powerful are Graph Neural Networks?](https://mlsanity.com/paper/1810.00826/) (2018)
- [AtomNet: A Deep Convolutional Neural Network for Bioactivity Prediction in Structure-based Drug Discovery](https://mlsanity.com/paper/1510.02855/) (2015)

## Abstract (arXiv)

The first step in drug discovery is finding drug molecule moieties with medicinal activity against specific targets. Therefore, it is crucial to investigate the interaction between drug-target proteins and small chemical molecules. However, traditional experimental methods for discovering potential small drug molecules are labor-intensive and time-consuming. There is currently a lot of interest in building computational models to screen small drug molecules using drug molecule-related databases. In this paper, we propose a method for predicting drug-target binding affinity using deep learning models. This method uses a modified GRU and GNN to extract features from the drug-target protein sequences and the drug molecule map, respectively, to obtain their feature vectors. The combined vectors are used as vector representations of drug-target molecule pairs and then fed into a fully connected network to predict drug-target binding affinity. This proposed model demonstrates its accuracy and effectiveness in predicting drug-target binding affinity on the DAVIS and KIBA datasets.